Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 02:30PM GMT
Release Date Price: €59.02 (+1.65%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. I'm Salveen Richter. Thanks for joining us. I'm the biotechnology analyst at Goldman Sachs. And with us, we're really pleased to have Denali and Ryan Watts, the CEO.

Brian, thanks so much for being here. And to start, could you just remind us of the clinical data that is expected across your portfolio for the remainder of this year? And as we look to next year, in what you are most focused on?

Questions & Answers

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Salveen, grateful -- really grateful to be here and thank you for the invitation. It's exciting to be with you at such an exciting time in neurodegeneration drug discovery and research, I think we're on the cusp of, I think, really important medicines for patients.

And so you asked about what to expect from Denali in the next 6 to 12 months. And let me just start by saying we have 5 clinical stage programs across different therapeutic areas and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot